ArticleKidney international reports2022
Three-Year Clinical Outcomes of the First South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort.
Article in Kidney international reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 3 syntheses or guidelines pooled it, 15 citations in OpenAlex.
- The Association between Low-Grade Proteinuria and Adverse Kidney Outcomes in IgA Nephropathy: A Systematic Review and Meta-Analysis.Clinical journal of the American Society of Nephrology : CJASN · 2026Pooled it
- Association Between Surrogate Endpoints and Clinical Outcomes in Immunoglobulin A Nephropathy: A Systematic Literature Review.Advances in therapy · 2025Pooled it
- Sexually dimorphic response to tobacco in the development of chronic kidney disease: a systematic review.BMC nephrology · 2024Pooled it
- Generic Controlled-Release Budesonide in IgA Nephropathy - A Single Center Retrospective Study.Kidney international reports · 2026Article
- The role of mucosal immune dysregulation in the pathogenesis of immunoglobulin A nephropathy.Frontiers in immunology · 2026Review
- Case Report: Successful telitacicept treatment for IgA nephropathy with stage 4 chronic kidney disease and acute renal failure.Frontiers in immunology · 2026Article
- Defining Disease Modification in IgA Nephropathy: Toward a Paradigm Shift in Management.Kidney international reports · 2025Review
- Serum IgA/C3 ratio as a diagnostic and prognostic biomarker for IgA nephropathy.Scientific reports · 2025Article
- Clinical Practice Patterns in IgA Nephropathy: A Global Questionnaire-Based Survey.Kidney international reports · 2023Article
- Clinicopathological Characteristics of Adult IgA Nephropathy in the United States.Kidney international reports · 2023Article
- The International IgA Nephropathy Network Prediction Tool Underestimates Disease Progression in Indian Patients.Kidney international reports · 2022Article
- Glomerulonephritis After Renal Transplatation in South Asia - Single Center Experience Over 5 Decades.Indian journal of nephrologyArticle
- State-of-Art Therapeutics in IgA Nephropathy.Indian journal of nephrologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 4 countries.
Funding
Abstract
introductionGlomerular Research And Clinical Experiments-IgA Nephropathy in Indians (GRACE-IgANI) is the first prospective South Asian IgA nephropathy (IgAN) cohort with prespecified objectives, protocolized longitudinal follow-up, and extensive biosample collection. The baseline risk scores predicted high risk of kidney disease progression.
methodsA total of 195 of 201 patients (97%) completed 3-year follow-up in September 2020. All patients received optimized supportive care, and those at high risk of progression were offered systemic corticosteroids.
resultsA total of 76 patients (76 of 193, 39.4%) had rapid progression in 3 years (≥5 ml/min per 1.73 m
conclusionWe identified longitudinal clinical variables measured at 6 months and ≥5 ml/min per 1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.